1. Home
  2. NGVC vs ENGN Comparison

NGVC vs ENGN Comparison

Compare NGVC & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natural Grocers by Vitamin Cottage Inc.

NGVC

Natural Grocers by Vitamin Cottage Inc.

HOLD

Current Price

$25.94

Market Cap

744.4M

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$7.57

Market Cap

647.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGVC
ENGN
Founded
1955
1999
Country
United States
Canada
Employees
N/A
82
Industry
Food Chains
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
744.4M
647.1M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
NGVC
ENGN
Price
$25.94
$7.57
Analyst Decision
Strong Buy
Buy
Analyst Count
1
6
Target Price
$36.00
$21.08
AVG Volume (30 Days)
104.7K
239.1K
Earning Date
05-07-2026
03-09-2026
Dividend Yield
2.28%
N/A
EPS Growth
36.05
N/A
EPS
0.49
N/A
Revenue
N/A
N/A
Revenue This Year
$7.08
N/A
Revenue Next Year
$6.04
N/A
P/E Ratio
$53.63
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.47
$2.66
52 Week High
$60.84
$12.25

Technical Indicators

Market Signals
Indicator
NGVC
ENGN
Relative Strength Index (RSI) 51.43 53.21
Support Level $24.13 $6.04
Resistance Level $26.69 $8.36
Average True Range (ATR) 0.80 0.51
MACD 0.04 0.17
Stochastic Oscillator 57.74 96.70

Price Performance

Historical Comparison
NGVC
ENGN

About NGVC Natural Grocers by Vitamin Cottage Inc.

Natural Grocers by Vitamin Cottage Inc operates natural and organic grocery and dietary supplement stores. It offers the following product categories, natural and organic food, dietary supplements, natural body care, household, pet care products, books and handouts. The Company has a single reporting segment, natural and organic retail stores, through which business are conducted. The company generates the majority of its revenue from grocery products and dietary supplements and rest from other products.

About ENGN enGene Holdings Inc.

enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Share on Social Networks: